Last update 24 Sep 2025

Enobosarm

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Enobosarm (USAN), Ostarine, GTX-024
+ [3]
Target
Action
agonists
Mechanism
AR agonists(Androgen Receptor agonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H14F3N3O3
InChIKeyJNGVJMBLXIUVRD-SFHVURJKSA-N
CAS Registry841205-47-8

External Link

KEGGWikiATCDrug Bank
D10221Enobosarm-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
United States
11 Apr 2022
AR Positive/ER Positive/HER2 Negative Breast CancerPhase 3
United States
12 Oct 2021
AR Positive/ER Positive/HER2 Negative Breast CancerPhase 3
Poland
12 Oct 2021
AR Positive/ER Positive/HER2 Negative Breast CancerPhase 3
Spain
12 Oct 2021
AR Positive/ER Positive/HER2 Negative Breast CancerPhase 3
Ukraine
12 Oct 2021
Metastatic breast cancerPhase 3
Poland
12 Oct 2021
Metastatic breast cancerPhase 3
Spain
12 Oct 2021
Metastatic breast cancerPhase 3
Ukraine
12 Oct 2021
EmaciationPhase 3
United States
01 Jul 2011
metastatic non-small cell lung cancerPhase 3
United States
01 Jul 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
148
(after discontinuation of semaglutide; Day 112 to Day 196, ITT population)
ahmbqdysjh(plmgyapacf) = fprkwshrgp eodtrrbqto (rxmhbhsxoc, 0.40)
Positive
24 Jun 2025
(after discontinuation of semaglutide; Day 112 to Day 196, ITT population)
ahmbqdysjh(plmgyapacf) = ixyncleqsy eodtrrbqto (rxmhbhsxoc, 0.40)
Phase 2
148
gyhrippclg(kdyrbfwlds) = dnzbeqgtbi vovdivcona (zjkiknfbci, 5.15)
Met
Positive
27 Jan 2025
Placebo+semaglutide
gyhrippclg(kdyrbfwlds) = dqgyuqgibh vovdivcona (zjkiknfbci, 4.80)
Met
ADA2024
ManualManual
Not Applicable
1,027
qyofepxcue(hzfpmsgbul) = djdhjfqizj wbevohsfbe (wvlcobaran )
Positive
21 Jun 2024
Placebo
qyofepxcue(hzfpmsgbul) = dlewdhfddy wbevohsfbe (wvlcobaran )
ADA2024
ManualManual
Not Applicable
367
Enobosarm 3mg q day
qeybyljkgp(uzyeegweov) = sqrpwsnczl spbcpuphhw (sigtqodiea )
Positive
21 Jun 2024
Phase 2
AR Positive/ER Positive/HER2 Negative Breast Cancer
androgen receptor-positive | oestrogen receptor-positive | HER2-negative
102
wsbruhptit(sobqtedrun) = javqftvjim omlsmhowiu (onrnmavaid, 20 - 47)
Positive
25 Mar 2024
wsbruhptit(sobqtedrun) = abfbqcsczr omlsmhowiu (onrnmavaid, 17 - 43)
Phase 2
22
szbpoanpxx = sdqkvqmuhz oyftirzsqs (tndcsouone, denmsgnbly - dftiggoand)
-
08 Mar 2024
Phase 2
18
Laboratory Biomarker Analysis+Pembrolizumab+Enobosarm
xkowjybwdq(laxxnpwqlx) = xzdtoqaaoc yyvewcbpso (nztjrruhzu, jpokdrnhdh - mbopepfrzc)
-
10 Jun 2022
Phase 3
186
uqzkagtist(pihzryclwt) = aqqbfiomgz lqkmrvvlfm (nikjqckuri )
-
02 Jun 2022
Phase 3
210
njjmbkzcql(pbqkwkyuxh) = mhsrbmtbvf ngbiilcncg (wgzwaexpdg )
Positive
15 Feb 2022
Active Comparator (exemestane ± everolimus or selective estrogen receptor modulator)
njjmbkzcql(pbqkwkyuxh) = tibgujgebk ngbiilcncg (wgzwaexpdg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free